Eliglustat is an inhibitor of the enzyme glucosylceramide synthase used in the treatment for Gaucher's disease. The drug is predominantly metabolized by cytochrome CYP2D6 and to a lesser extent by CYP3A.
Eliglustat (Adverse Reactions)
Eliglustat is a drug that is classified within a group of substances used to treat inborn errors of metabolism (called enzyme inhibitors). It is used to treat Gaucher's disease type 1, a disease in which certain fatty substances are not broken down normally and accumulate in some organs, causing liver, spleen, bone, and hematological problems. Eliglustat prevents the body from producing these fatty substances so that they accumulate in a lower concentration in the body.
MECHANISM OF ACTION
Eliglustat is a potent and specific inhibitor of glucosylceramide synthase that acts as a substrate reduction therapy (SRT) for Gaucher disease. The goal of SRT is to reduce the rate of synthesis of the primary substrate glucosylceramide (GL-1) to match the altered rate of catabolism in patients, thus preventing the accumulation of glucosylceramide and alleviating clinical manifestations.
CONTRAINDICATIONS
Eliglustat is contraindicated in:
- Patients who are hypersensitive to this drug.
- Patients who are taking concomitantly another strong or moderate CYP2D6 inhibitor PLUS another drug that strongly or moderately inhibits CYP3A and are normal or intermediate CYP2D6 metabolizers.
- CYP2D6 poor metabolizers who are receiving a moderate or strong CYP3A inhibitor.
INTERACTIONS
If eliglustat is administered with a drug that strongly induces CYP3A activity, the desired therapeutic effect is unlikely to be achieved, so co-administration with strong CYP3A inducers is not recommended.
Examples of CYP2D6 and CYP3A inhibitors:
- Strong CYP2D6 inhibitor: paroxetine, fluoxetine, quinidine, bupropion
- Moderate CYP2D6 inhibitor: duloxetine, terbinafine, moclobemide, mirabegron, cinacalcet, dronedarone
- Strong CYP3A inhibitor: ketoconazole, clarithromycin, itraconazole, cobicistat, indinavir, lopinavir, ritonavir, saquinavir, telaprevir, tipranavir, posaconazole, voriconazole, telithromycin, conivaptan, boceprevir.
- Moderate CYP3A inhibitor: erythromycin, ciprofloxacin, fluconazole, diltiazem, verapamil, aprepitant, atazanavir, darunavir, fosamprenavir, imatinib, cimetidine.
- Weak CYP3A inhibitor: amlodipine, cilostazol, fluvoxamine, goldenseal, isoniazid, ranitidine, ranolazine
Examples of strong CYP3A inducers: rifampicin, carbamazepine, phenobarbital, phenytoin, rifabutin, St. John's Wort.
SIDE EFFECTS
Side effects of treatment with eliglustat include nausea, diarrhea, abdominal pain, flatulence, fatigue, headache, back and joint pain.
BRAND NAME
- Cerdelga®
Genes analyzed
Bibliography
Kane M, Dean L. Eliglustat Therapy and CYP2D6 Genotype. 2020 Dec 22. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.
Sahasrabudhe SA, Cheng S, Al-Kofahi M, et al. Physiologically-Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug-Drug Interactions. Clin Pharmacol Ther. 2022 Dec;112(6):1254-1263.
